1. U.S. Department of Health and Human Services, Food and Drug Administration. Non-inferiority clinical trials to establish effectiveness. In: Guidance for industry; 2016.
https://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf
. Accessed 11 Sept 2018.
2. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295(10):1152–60.
3. ICH Harmonised Tripartite Guideline. Choice of control group and related issues in clinical trials. E10. 2000.
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf
. Accessed 11 Sept 2018.
4. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. 2000.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003658.pdf
. Accessed 11 Sept 2018.
5. Mauri L, D'Agostino RB Sr. Challenges in the design and interpretation of noninferiority trials. N Engl J Med. 2017;377(14):1357–67.